中药调控铁死亡在血液系统恶性肿瘤中作用的研究进展  

Progress in role of traditional Chinese medicine regulating ferroptosis in hematological malignancies

作　　者：魏雨欣 韩炯萍 杨益凡 封蔚莹[2] WEI Yuxin;HAN Jiongping;YANG Yifan;FENG Weiying(School of Medicine,Shaoxing University,Shaoxing 312000,China;Department of Hematology,Shaoxing People's Hos-pital,Shaoxing 312000,China)

机构地区：[1]绍兴文理学院医学院,浙江绍兴312000 [2]绍兴市人民医院血液科,浙江绍兴312000

出　　处：《中国病理生理杂志》2025年第4期809-815,共7页Chinese Journal of Pathophysiology

基　　金：浙江省自然科学基金资助项目(No.LBY23H080002);浙江省医药卫生科技计划项目(No.2023KY348);浙江省卫生高层次人才-创新人才(浙卫办[2022]32号)。

摘　　要：血液系统恶性肿瘤是一类始于造血组织或免疫系统的肿瘤。铁死亡是一种新型细胞程序性死亡方式,通过铁代谢、氧化防御和脂质过氧化等多种作用机制发挥作用。近年来,研究显示血液系统恶性肿瘤与铁死亡关系密切,中药在其治疗中发挥积极作用。本文综述铁死亡的作用机制,中药活性成分及中药单体通过铁死亡途径干预白血病、淋巴瘤和骨髓瘤等血液系统恶性肿瘤的研究现状,以期为中药靶向铁死亡治疗血液系统恶性肿瘤提供参考资料。Hematologic malignancies arise from hematopoietic or immune system tissues and are characterized by abnormal cellular growth.Ferroptosis,a newly recognized form of cell death,is driven by mechanisms such as iron metabolism,oxidative defense,and lipid peroxidation.Increasing evidence has highlighted a significant link between ferroptosis and various hematologic cancers.Traditional Chinese medicine(TCM)has shown particular promise in the treatment of these cancers,offering unique therapeutic approaches.This article explores the role of ferroptosis modulation in hematologic malignancies and reviews the current understanding of how TCM's bioactive compounds and monomers exert their effects in managing hematologic cancers,including leukemia,lymphoma,and multiple myeloma,through the induction of ferroptosis.The objective is to provide insight into potential strategies for targeting ferroptosis as a treatment approach for these malignancies.

关 键 词：铁死亡 血液系统肿瘤 中药 信号通路 

分 类 号：R363[医药卫生—病理学] R453[医药卫生—基础医学] R733.3